Global Endometriosis Market Report 2024: Key Therapies, Market Drivers, and Competitive Landscape

"The Business Research Company recently released a comprehensive report on the Global Endometriosis Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.

According to The Business Research Company's, The endometriosis market size has grown rapidly in recent years. It will grow from $1.27 billion in 2023 to $1.4 billion in 2024 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to delayed diagnosis and increased awareness, advances in laparoscopic surgery, hormonal therapies, patient advocacy and support groups.

The endometriosis market size is expected to see strong growth in the next few years. It will grow to $2.01 billion in 2028 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to minimally invasive procedures, pharmaceutical innovations, genetic and epigenetic research, global expansion of women's healthcare. Major trends in the forecast period include patient-centered care, precision medicine, virtual care and telemedicine, fertility preservation.

Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/endometriosis-global-market-report

Market Drivers and Trends:

The increasing incidence of ovarian cancer is expected to propel the growth of the endometriosis market going forward. Ovarian cancer is a type of cancer that begins in the ovaries, the female reproductive organs responsible for producing eggs and the hormones estrogen and progesterone. Endometriosis is associated with an increased risk of developing epithelial ovarian cancer, mainly the endometrioid and precise cell cancer subtypes, characterized by high estrogen concentrations, which can increase the risk of developing ovarian cancer. For instance, in January 2023, according to the American Cancer Society, a US-based professional organization, it is projected that approximately 19,710 new cases of ovarian cancer will be diagnosed among women in the US in 2023. Furthermore, in 2022, according to the Ovarian Cancer Research Alliance, a US-based not-for-profit organization, ovarian cancer caused 12,810 deaths in 2022 and increased to 13,270 fatalities in 2023. Therefore, the increasing incidence of ovarian cancer is driving the growth of the endometriosis market.

Major companies operating in the endometriosis market are focused on developing innovative drugs such as Myfembree and getting approvals to provide new patient treatment options. The introduction of novel endometriosis medications addresses a previously unmet demand for effective treatments. For instance, in August 2022, Myovant Sciences GmbH, a Switzerland-based biopharmaceutical company and Pfizer Inc., a US-based pharmaceutical industry company, received approval for Myfembree from the U.S. Food and Drug Administration (FDA) for the management of moderate to severe pain associated with endometriosis in premenopausal women. Myfembree is a once-daily pill that combines three essential ingredients such as relugolix, estradiol and norethindrone acetate. It provides proven relief for premenopausal women with two indications in one pill. This provides an alternative treatment option for women who cannot or prefer not to use hormone therapy.

Key Benefits for Stakeholders:

• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.

Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=13035&type=smp

Major Key Players of the Market:

Pfizer Inc., F. Hoffmann-La Roche AG, Merck And Co. Inc., Abbvie Inc., Bayer AG, Bristol-Myers Squibb Company, GlaxoSmithKline PLC, AstraZeneca PLC, Abbott Laboratories, Eli Lilly and Company, Mylan N.V., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Limited, Ipsen Pharma Biotech S.A.S., Cadila Pharmaceuticals Ltd., Gedeon Richter PLC, Torrent Pharmaceuticals Ltd., Neurocrine Biosciences Inc., Ferring Pharmaceuticals, Prestige Consumer Healthcare Inc., Almirall S.A, Evotec BioSystems GmbH, Serum Institute of India Pvt. Ltd., Kissei Pharmaceutical Co. Ltd., Sanofi India Ltd., DebioPharm Group, Repros Therapeutics Inc., Meditrina Pharmaceuticals Private Limited, Zenomed Healthcare Private Limited.

Endometriosis Market 2024 Key Insights:

• The endometriosis is expected to grow to $2.01 billion in 2028 at a compound annual growth rate (CAGR) of 9.3%.
• Elevated Ovarian Cancer Incidence Fuels Growth In The Endometriosis Market
• Innovative Medications Reshaping Endometriosis Treatment Landscape
• North America was the largest region in the endometriosis market in 2023. The regions covered in endometriosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=13035&type=smp

Contact Us:

The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ "

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.